A recent meta-analysis suggests there may be no meaningful overall survival benefit from adding hormone therapy to early salvage postoperative radiotherapy (PORT) in patients with prostate cancer who ...
Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results